Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment.
Standard
Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment. / Blennow, K; De Meyer, G; Hansson, O; Minthon, L; Wallin, A; Zetterberg, H; Lewczuk, P; Vanderstichele, H; Vanmechelen, E; Kornhuber, J; Wiltfang, J; Heuser, I; Maier, W; Luckhaus, C; Rüther, E; Hüll, M; Jahn, Holger; Gertz, H J; Frölich, L; Hampel, H; Pernetzki, R.
in: J NUTR HEALTH AGING, Jahrgang 13, Nr. 3, 3, 2009, S. 205-208.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment.
AU - Blennow, K
AU - De Meyer, G
AU - Hansson, O
AU - Minthon, L
AU - Wallin, A
AU - Zetterberg, H
AU - Lewczuk, P
AU - Vanderstichele, H
AU - Vanmechelen, E
AU - Kornhuber, J
AU - Wiltfang, J
AU - Heuser, I
AU - Maier, W
AU - Luckhaus, C
AU - Rüther, E
AU - Hüll, M
AU - Jahn, Holger
AU - Gertz, H J
AU - Frölich, L
AU - Hampel, H
AU - Pernetzki, R
PY - 2009
Y1 - 2009
N2 - OBJECTIVE: To better understand the seemingly contradictory plasma beta-amyloid (Abeta) results in Alzheimer's disease (AD) patients by using a newly developed plasma Abeta assay, the INNO-BIA plasma Abeta forms, in a multicenter study. METHODS: A combined retrospective analysis of plasma Abeta isoforms on mild cognitive impairment (MCI) from three large cross-sectional studies involving 643 samples from the participating German and Swedish centers. RESULTS: Detection modules based on two different amino (N)-terminal specific Abeta monoclonal antibodies demonstrated that Abeta in plasma could be reliable quantified using a sandwich immunoassay technology with high precision, even for low Abeta42 plasma concentrations. Abeta40 and Abeta42 concentrations varied consistently with the ApoE genotype, while the Abeta42/Abeta40 ratio did not. Irrespective of the decrease of the Abeta42/Abeta40 ratio with age and MMSE, this parameter was strongly associated with AD, as defined in this study by elevated hyperphosphorylated (P-tau181P) levels in cerebrospinal fluid (CSF). CONCLUSION: A highly robust assay for repeatedly measuring Abeta forms in plasma such as INNO-BIA plasma Abeta forms might be a useful tool in a future risk assessment of AD.
AB - OBJECTIVE: To better understand the seemingly contradictory plasma beta-amyloid (Abeta) results in Alzheimer's disease (AD) patients by using a newly developed plasma Abeta assay, the INNO-BIA plasma Abeta forms, in a multicenter study. METHODS: A combined retrospective analysis of plasma Abeta isoforms on mild cognitive impairment (MCI) from three large cross-sectional studies involving 643 samples from the participating German and Swedish centers. RESULTS: Detection modules based on two different amino (N)-terminal specific Abeta monoclonal antibodies demonstrated that Abeta in plasma could be reliable quantified using a sandwich immunoassay technology with high precision, even for low Abeta42 plasma concentrations. Abeta40 and Abeta42 concentrations varied consistently with the ApoE genotype, while the Abeta42/Abeta40 ratio did not. Irrespective of the decrease of the Abeta42/Abeta40 ratio with age and MMSE, this parameter was strongly associated with AD, as defined in this study by elevated hyperphosphorylated (P-tau181P) levels in cerebrospinal fluid (CSF). CONCLUSION: A highly robust assay for repeatedly measuring Abeta forms in plasma such as INNO-BIA plasma Abeta forms might be a useful tool in a future risk assessment of AD.
M3 - SCORING: Zeitschriftenaufsatz
VL - 13
SP - 205
EP - 208
JO - J NUTR HEALTH AGING
JF - J NUTR HEALTH AGING
SN - 1279-7707
IS - 3
M1 - 3
ER -
